These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27270157)

  • 1. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia.
    Doshi JA; Li P; Huo H; Pettit AR; Kumar R; Weiss BM; Huntington SF
    Am J Manag Care; 2016 Mar; 22(4 Suppl):s78-86. PubMed ID: 27270157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma.
    Li P; Wong YN; Jahnke J; Pettit AR; Doshi JA
    Cancer Med; 2018 Jan; 7(1):75-86. PubMed ID: 29195016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specialty Tier-Level Cost Sharing and Biologic Agent Use in the Medicare Part D Initial Coverage Period Among Beneficiaries With Rheumatoid Arthritis.
    Doshi JA; Hu T; Li P; Pettit AR; Yu X; Blum M
    Arthritis Care Res (Hoboken); 2016 Nov; 68(11):1624-1630. PubMed ID: 27014854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".
    Doshi JA; Li P; Pettit AR; Dougherty JS; Flint A; Ladage VP
    Am J Manag Care; 2017 Mar; 23(3 Suppl):S39-S45. PubMed ID: 29648739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
    Phuar HL; Begley CE; Chan W; Krause TM
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1140-1150. PubMed ID: 31556823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How Low-Income Subsidy Recipients Respond to Medicare Part D Cost Sharing.
    Stuart B; Hendrick FB; Xu J; Dougherty JS
    Health Serv Res; 2017 Jun; 52(3):1185-1206. PubMed ID: 27324201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
    Seymour EK; Ruterbusch JJ; Winn AN; George JA; Beebe-Dimmer JL; Schiffer CA
    Cancer; 2021 Jan; 127(1):93-102. PubMed ID: 33119175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis.
    Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
    J Manag Care Spec Pharm; 2015 Oct; 21(10):956-64. PubMed ID: 26402394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effects of Cost Sharing on Adherence to Medications Prescribed for Concurrent Use: Do Definitions Matter?
    Sacks NC; Burgess JF; Cabral HJ; McDonnell ME; Pizer SD
    J Manag Care Spec Pharm; 2015 Aug; 21(8):678-87. PubMed ID: 26233540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.
    Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
    J Manag Care Spec Pharm; 2014 Aug; 20(8):862-76. PubMed ID: 25062080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
    Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
    Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Financial Burden for Patients With Chronic Myeloid Leukemia Enrolled in Medicare Part D Taking Targeted Oral Anticancer Medications.
    Shen C; Zhao B; Liu L; Shih YT
    J Oncol Pract; 2017 Feb; 13(2):e152-e162. PubMed ID: 28095170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosis.
    Hartung DM; Johnston KA; McGregor JC; Bourdette DN
    Mult Scler Relat Disord; 2020 Nov; 46():102554. PubMed ID: 33032059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Cost-Sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study.
    Li P; Hu T; Yu X; Chahin S; Dahodwala N; Blum M; Pettit AR; Doshi JA
    Health Serv Res; 2018 Aug; 53 Suppl 1(Suppl Suppl 1):2735-2757. PubMed ID: 28736929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
    Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
    J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-gap discounts in Medicare Part D and specialty drug use.
    Jung J; Xu WY; Cheong C
    Am J Manag Care; 2017 Sep; 23(9):553-559. PubMed ID: 29087157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.
    Shanafelt TD; Borah BJ; Finnes HD; Chaffee KG; Ding W; Leis JF; Chanan-Khan AA; Parikh SA; Slager SL; Kay NE; Call TG
    J Oncol Pract; 2015 May; 11(3):252-8. PubMed ID: 25804983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
    Winn AN; Keating NL; Dusetzina SB
    J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myopic and Forward Looking Behavior in Branded Oral Anti-Diabetic Medication Consumption: An Example from Medicare Part D.
    Sacks NC; Burgess JF; Cabral HJ; Pizer SD
    Health Econ; 2017 Jun; 26(6):753-764. PubMed ID: 27150938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.
    Shen C; Zhao B; Liu L; Shih YT
    Cancer; 2018 Jan; 124(2):364-373. PubMed ID: 28976559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.